Reuters Pharma USA 2024 – Jeffrey Meckler
Most of the exciting work being done right now in cancer immunotherapy is centred on highly targeted approaches that aim to activate only the most necessary immune responses to eliminate a particular tumour. But Jeffrey Meckler, CEO of Indaptus Therapeutics, says his company’s early work could turn that paradigm on its head.
At Reuters Pharma USA in Philadelphia in March, pharmaphorum editor-in-chief Jonah Comstock caught up with Meckler to learn more about his company’s holistic approach to immunotherapy.
Meckler describes how chemically and genetically modified bacteria can potentially activate the entire immune system in short bursts, generating increased efficacy either alone or in combination with targeted therapies.
The company is still in the early stages of the work, but it has potential to be viable in a broad range of conditions. Check out the video below to hear more about the work Indaptus is doing and what they hope to find as their preclinical research continues.
